Inflammatory factor in the clinical picture and therapy of irritable bowel syndrome
https://doi.org/10.21518/2079-701X-2018-14-67-72
Abstract
The article shows the dynamics of evaluation of prognostic factors of irritable bowel syndrome. Evolution of the views indicates an increasing evaluation of inflammation and the role of markers of inflammation of cytokines, especially alpha-TNF in clinical manifestations. The rationale for using a complex drug based on affinity purified release-active antibodies to alpha-TNF, to the brain-specific protein S-100 and histamine-colourant is presented.
About the Authors
V. M. Makhov
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
A. A. Balakhonov
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
M. A. Isaikina
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
Yu. A. Doronina
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Irritable bowel syndrome in the light of Rome IV recommendations, therapeutic approaches. Materials of the 27th scientific and practical conference Digestive System Diseases, Pharmacotherapy from the Perspective of Evidence-Based Medicine. M., 2018.
2. Drossman DA. Functional gastrointestinal disorders and the Rome III process. Gastroenterology, 2006, 130(s): 1377-1390.
3. Makhov VM, Romasenko LV, Turko TV, Sheptak, NN. Irritable bowel syndrome: comorbid somatopsychic disease. Dokazatelnaya Gastroenterologiya, 2014, 3 (2): 56-61.
4. Lacy BE et al. Bowel disorders. Gastroenterology, 2016, 150(6): 1393-1407.
5. Shevyakova AM, et al. Irritable bowel syndrome as a conflict-generating factor in the gastroenterology practice. 2018.
6. Parfenov AI, Ruchkina IN. Post-infectious irritable bowel syndrome. Lechashchy Vrach, 2010, 7: 16-19.
7. Pimenyel M, Park S, Mirocha J et al. The effect oa a non-absorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med, 2006, 145: 557-563.
8. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol, 2010, 7(3): 163-173.
9. Sinagra E, Pompei G, Tomasello G et al. Inflammation in irritable bowel syndrome: Myth or new treatment target? World J Gastroenterol 2016, 22 (7): 2242-2255.
10. El-Salhy M, Gundersen D, Gilja OH et al. Is irritable bowel syndrome an organic disorder? World J of Gastroenterology: WJG, 2014, 20(2): 384-400.
11. Rodionova ON, et al. Neurohumoral and cytokine imbalance in patients with functional diseases of the gastrointestinal tract. Volgogradskiy NauchnoMeditsinskiy Zhurnal, 2008, 4 (20).
12. Bashashati M et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta‐analysis. Neurogastroenterology & Motility, 2014, 26(7): 1036-1048.
13. Vidiker RV, Polyakova NA. Comparative analysis of serum TNF-α, IL-1β, IL-6, IL-8 and IL-10 levels in patients with irritable bowel syndrome depending on the clinical variant of the course. Vestnik Sovremennykh Issledovaniy, 2017, 11-1: 48-49
14. Dignass A, Lindsay J, Sturm A, Windsor A, Colombel JF, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis, 2010, 4(1): 28-62.
15. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev, 2014. CD005112.
16. Smith R. S. The macrophage theory of depression (published erratum appears in Med Hypotheses, 1991, 36: 178). Med Hypotheses, 1991, 35: 298-306.
17. Maes M, Bosmans E, Suy E et al. Depressionrelated distur- bances in mitоgen-induced lymphocyte responses and interleukin- 1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand, 1991, 84: 379-386.
18. Zorrilla EP, Luborsky L, McKay JR et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun, 2001, 15: 199-226.
19. Lotrich FE, El-Gabalawy H, Guenther LC, Ware CF. The role of inflammation in the pathophysiology of depression: different treatments and their effects. Rheumatol, 2011, 38(Suppl 88): 48-54.
20. Hayley S. Toward an anti-inflammatory strategy for depression. Frontiers in Behav Neurosci, 2011, 5: 19.
21. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol, 2011, 106: 644-659.
22. Kazyulin AN. Kolofort: the mechanism of action and the potential for pathogenetic therapy of diseases of the gastrointestinal tract. Gastroenterologiya Sankt-Peterburga, 2016, 1-2: 19-23.
23. Avalueva EB, et al. Efficacy and safety of the use of Kolofort in irritable bowel syndrome: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Gastroenterologiya. Supplement to Journal Consilium Medicum, 2014, 1: 43-50.
24. Maev IV, et al. Clinical efficacy and safety of treatment regimens for irritable bowel syndrome (comparative study results). Consilium Medicum, 2016, 18 (8): 19-26.
25. Tsukanov VV, et al. The efficacy of Kolofort in the treatment of patients with irritable bowel syndrome. Terapevticheskiy Arkhiv (archive until 2018), 2016, 88 (8): 40-45.
26. Osadchuk MA, Burdina VO. New pathogenetic approaches to the treatment of irritable bowel syndrome based on morpho-functional features of this pathology. Pract. meditsyna, 2014, 1 (77): 12-20
Review
For citations:
Makhov VM, Balakhonov AA, Isaikina MA, Doronina YA. Inflammatory factor in the clinical picture and therapy of irritable bowel syndrome. Meditsinskiy sovet = Medical Council. 2018;(14):67-72. (In Russ.) https://doi.org/10.21518/2079-701X-2018-14-67-72
Views:
643
Email this article 